Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1994 1
1998 1
2001 1
2002 1
2005 1
2006 3
2007 1
2008 4
2009 2
2010 1
2011 1
2012 2
2013 5
2014 3
2015 3
2016 2
2017 3
2018 7
2019 8
2020 9
2021 14
2022 9
2023 7

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology.
Vonk-Noordegraaf A, Haddad F, Chin KM, Forfia PR, Kawut SM, Lumens J, Naeije R, Newman J, Oudiz RJ, Provencher S, Torbicki A, Voelkel NF, Hassoun PM. Vonk-Noordegraaf A, et al. Among authors: chin km. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D22-33. doi: 10.1016/j.jacc.2013.10.027. J Am Coll Cardiol. 2013. PMID: 24355638 Free article. Review.
Selexipag for the Treatment of Pulmonary Arterial Hypertension.
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV; GRIPHON Investigators. Sitbon O, et al. Among authors: chin km. N Engl J Med. 2015 Dec 24;373(26):2522-33. doi: 10.1056/NEJMoa1503184. N Engl J Med. 2015. PMID: 26699168 Free article. Clinical Trial.
Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension.
Galiè N, Gaine S, Channick R, Coghlan JG, Hoeper MM, Lang IM, McLaughlin VV, Lassen C, Rubin LJ, Hsu Schmitz SF, Sitbon O, Tapson VF, Chin KM. Galiè N, et al. Among authors: chin km. Adv Ther. 2022 Jan;39(1):796-810. doi: 10.1007/s12325-021-01898-1. Epub 2021 Oct 30. Adv Ther. 2022. PMID: 34727317 Free PMC article. Clinical Trial.
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study.
Rosenkranz S, Channick R, Chin KM, Jenner B, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, McLaughlin VV, Du Roure C, Rubin LJ, Sitbon O, Tapson V, Lang IM. Rosenkranz S, et al. Among authors: chin km. Eur J Heart Fail. 2022 Jan;24(1):205-214. doi: 10.1002/ejhf.2369. Epub 2021 Nov 21. Eur J Heart Fail. 2022. PMID: 34806261 Free PMC article. Clinical Trial.
Pulmonary arterial hypertension.
Chin KM, Rubin LJ. Chin KM, et al. J Am Coll Cardiol. 2008 Apr 22;51(16):1527-38. doi: 10.1016/j.jacc.2008.01.024. J Am Coll Cardiol. 2008. PMID: 18420094 Free article. Review.
Lessons from the COMPASS-3 Study.
Shah T, Chin KM. Shah T, et al. Among authors: chin km. Pulm Circ. 2018 Jan-Mar;8(1):2045893218757100. doi: 10.1177/2045893218757100. Pulm Circ. 2018. PMID: 29384427 Free PMC article. No abstract available.
79 results